Disclosures for "Receptor Selectivity Profile and Clinical Significance of Ecopipam and Relevant Metabolites: A Potential New Treatment for Tourette Syndrome (TS)"
-
Dr. Wanaski has received personal compensation for serving as an employee of Paragon Biosciences. Dr. Wanaski has stock in Paragon Biosciences. Dr. Wanaski has stock in Emalex Biosciences.
-
Dr. Schmith has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Emalex Biosciences.
-
Dr. Karkanias has received personal compensation for serving as an employee of Emalex Biosciences, Inc.
-
Dr. Cunniff has received personal compensation for serving as an employee of Paragon Biosciences. Dr. Cunniff has stock in Harmony Biosciences. Dr. Cunniff has stock in Emalex Biosciences.